Related Experiment Videos
Liarozole (R75251) in hormone-resistant prostate cancer patients
G A Dijkman1, P Fernandez del Moral, J Bruynseels
1Department of Urology, Ignatius Hospital, Breda, The Netherlands.
Background:
Liarozole is an imidazole derivative that has been identified as an inhibitor of the cytochrome P450-dependent all-trans retinoid acid (RA) breakdown. RA is one of the principal endogenous compounds that controls growth and differentiation of epithelial tissues in mammals.
Methods:
Fifty-five patients with hormone-resistant prostate cancer in progression, following at least first-line androgen ablation therapy, were evaluated. Thirty-one patients were treated with liarozole 300 mg b.i.d., while 24 patients started with 150 mg b.i.d., which was increased to 300 mg b.i.d. after 4 or 8 weeks. Two patients were not evaluable because they withdrew after initial consent. The WHO performance status was 0 (n = 18), 1 (n = 22), 2 (n = 17), and 3 (n = 6). Most patients (80%) used analgesics.
Results:
For 11 out of the 53 patients, treatment lasted less than 1 month (they were therefore not evaluable for response) due to: poor compliance (n = 1); early death (n = 3); side-effects (n = 2); and decline of physical condition and continuous progression (n = 4). One patient refused to report for follow-up. In all responders, except one, the dose was increased to 300 mg b.i.d. In 23 of the 42 patients evaluable for response, the pain score improved. In 5 patients the pain score had reduced from 2 or 3 to 0. In 11 out of the 42 patients there was a 1-point improvement of WHO performance status. The prostatic-specific antigen (PSA) response rate was 41%; 15 out of 42 evaluable patients presented a decrease of > or = 50%, whereas PSA normalized in 2 further patients. Most of the side effects mimicked retinoid acid toxicity: cutaneous manifestations (such as dry skin, dry lips, sticky skin, brittle nails, erythema, or itch). All patients experienced one or more of these side effects. Other side effects include nausea, fatigue, and slight alopecia.
Conclusions:
Liarozole can be an enrichment of the therapeutic armamentarium for treatment of hormone-resistant prostate cancer patients after first-line androgen ablation therapy without serious toxicity.
Insights
Liarozole effectively treats hormone-resistant prostate cancer by inhibiting retinoid acid breakdown. This study shows improved pain and prostate-specific antigen levels with manageable side effects.
Area of Science:
- Oncology
- Pharmacology
Background:
- Liarozole is an imidazole derivative that inhibits cytochrome P450-dependent breakdown of all-trans retinoid acid (RA).
- Retinoid acid (RA) is crucial for regulating epithelial tissue growth and differentiation in mammals.
Purpose of the Study:
- To evaluate the efficacy and safety of liarozole in patients with hormone-resistant prostate cancer (HRPC).
- To assess liarozole's impact on pain, performance status, and prostate-specific antigen (PSA) levels in HRPC patients.
Main Methods:
- Fifty-five patients with progressive HRPC received liarozole at 300 mg b.i.d. or 150 mg b.i.d. escalated to 300 mg b.i.d.
- Patients' WHO performance status and analgesic use were recorded.
- Treatment duration and response were evaluated, with 42 patients assessable for response.
Main Results:
- Pain scores improved in 23 of 42 evaluable patients; 11 showed a 1-point improvement in WHO performance status.
- A 41% PSA response rate was observed (15 patients with > or = 50% decrease, 2 normalized).
- Common side effects included cutaneous manifestations mimicking retinoid acid toxicity, nausea, fatigue, and alopecia.
Conclusions:
- Liarozole offers a valuable addition to the treatment of hormone-resistant prostate cancer post-androgen ablation.
- The treatment demonstrated acceptable toxicity, with side effects primarily related to retinoid acid pathways.